Donovan G Kearns1,2,3,4, Shelley Uppal1,2,3,4, Vipawee S Chat1,2,3,4, Jashin J Wu1,2,3,4. 1. Mr. Kearns is with Loma Linda University School of Medicine in Loma Linda, California. 2. Dr. Uppal is with Albany Medical College School of Medicine in Albany, New York. 3. Ms. Chat is with the Medical College of Georgia at Augusta University in Augusta, Georgia. 4. Dr. Wu is with the Dermatology Research and Education Foundation in Irvine, California.
Abstract
BACKGROUND: Interleukin (IL)-17 inhibitors are a newer class of biologic used to treat patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. OBJECTIVE: We compared evidence-based clinical practice guidelines (CPGs) from leading dermatological organizations for the use of IL-17 inhibitors in psoriasis. METHODS: Guidelines from the Joint American Academy of Dermatology-National Psoriasis Foundation (AAD-NFP) Guidelines, British Association of Dermatologists guidelines (BAD), and European S3 group (ES3) were all reviewed and compared. RESULTS: This analysis revealed significant overlap in the recommendations made by experts from each CPG. However, our review highlights differences in routine laboratory recommendations and the relative and absolute contraindications to use with IL-17 inhibitors. CONCLUSION: IL-17 inhibitors are an effective treatment option for psoriasis. This analysis and review of guidelines for IL-17 inhibitor use highlights the consensus in treatment protocols and areas of disagreement between CPGs.
BACKGROUND: Interleukin (IL)-17 inhibitors are a newer class of biologic used to treat patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. OBJECTIVE: We compared evidence-based clinical practice guidelines (CPGs) from leading dermatological organizations for the use of IL-17 inhibitors in psoriasis. METHODS: Guidelines from the Joint American Academy of Dermatology-National Psoriasis Foundation (AAD-NFP) Guidelines, British Association of Dermatologists guidelines (BAD), and European S3 group (ES3) were all reviewed and compared. RESULTS: This analysis revealed significant overlap in the recommendations made by experts from each CPG. However, our review highlights differences in routine laboratory recommendations and the relative and absolute contraindications to use with IL-17 inhibitors. CONCLUSION: IL-17 inhibitors are an effective treatment option for psoriasis. This analysis and review of guidelines for IL-17 inhibitor use highlights the consensus in treatment protocols and areas of disagreement between CPGs.
Authors: A Nast; P I Spuls; G van der Kraaij; P Gisondi; C Paul; A D Ormerod; P Saiag; C H Smith; E Dauden; E M de Jong; E Feist; R Jobling; M Maccarone; U Mrowietz; K A Papp; K Reich; S Rosumeck; T Talme; H B Thio; P van de Kerkhof; R N Werner; C Dressler Journal: J Eur Acad Dermatol Venereol Date: 2017-09-11 Impact factor: 6.166
Authors: Alan Menter; Bruce E Strober; Daniel H Kaplan; Dario Kivelevitch; Elizabeth Farley Prater; Benjamin Stoff; April W Armstrong; Cody Connor; Kelly M Cordoro; Dawn M R Davis; Boni E Elewski; Joel M Gelfand; Kenneth B Gordon; Alice B Gottlieb; Arthur Kavanaugh; Matthew Kiselica; Neil J Korman; Daniela Kroshinsky; Mark Lebwohl; Craig L Leonardi; Jason Lichten; Henry W Lim; Nehal N Mehta; Amy S Paller; Sylvia L Parra; Arun L Pathy; Reena N Rupani; Michael Siegel; Emily B Wong; Jashin J Wu; Vidhya Hariharan; Craig A Elmets Journal: J Am Acad Dermatol Date: 2019-02-13 Impact factor: 11.527
Authors: Craig A Elmets; Craig L Leonardi; Dawn M R Davis; Joel M Gelfand; Jason Lichten; Nehal N Mehta; April W Armstrong; Cody Connor; Kelly M Cordoro; Boni E Elewski; Kenneth B Gordon; Alice B Gottlieb; Daniel H Kaplan; Arthur Kavanaugh; Dario Kivelevitch; Matthew Kiselica; Neil J Korman; Daniela Kroshinsky; Mark Lebwohl; Henry W Lim; Amy S Paller; Sylvia L Parra; Arun L Pathy; Elizabeth Farley Prater; Reena Rupani; Michael Siegel; Benjamin Stoff; Bruce E Strober; Emily B Wong; Jashin J Wu; Vidhya Hariharan; Alan Menter Journal: J Am Acad Dermatol Date: 2019-02-13 Impact factor: 11.527
Authors: Andrea Chiricozzi; Rosita Saraceno; Maria Vittoria Cannizzaro; Steven P Nisticò; Sergio Chimenti; Alessandro Giunta Journal: Dermatology Date: 2012-12-28 Impact factor: 5.366
Authors: Howa Yeung; Junko Takeshita; Nehal N Mehta; Stephen E Kimmel; Alexis Ogdie; David J Margolis; Daniel B Shin; Rosemary Attor; Andrea B Troxel; Joel M Gelfand Journal: JAMA Dermatol Date: 2013-10 Impact factor: 10.282
Authors: Richard B Warren; Melinda Gooderham; Russel Burge; Baojin Zhu; David Amato; Karen Huayu Liu; David Shrom; Jiaying Guo; Alan Brnabic; Andrew Blauvelt Journal: J Am Acad Dermatol Date: 2019-12-26 Impact factor: 11.527
Authors: Mark G Lebwohl; Kim A Papp; Lauren B Marangell; John Koo; Andrew Blauvelt; Melinda Gooderham; Jashin J Wu; Shipra Rastogi; Susan Harris; Radhakrishnan Pillai; Robert J Israel Journal: J Am Acad Dermatol Date: 2017-10-03 Impact factor: 11.527